United States of America based
Black Diamond Therapeutics Inc. is a venture-backed biotechnology company focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.
The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.
No pipelines published yet
No services posted yet